Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma

Postgraduate Medical Journal

Volumn 83, Issue 979, 2007, Pages 338-343

  Tang, Xiao Yan ^a   Zhu, You Qing ^a   Tao, Wen Hui ^a   Wei, Bai ^a   Lin, Xiao Ling ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; TRIPTOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER TOXICITY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DITERPENES; DRUG SYNERGISM; EPOXY COMPOUNDS; FLUOROURACIL; HT29 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHENANTHRENES; PLANT EXTRACTS; TRIPTERYGIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34249092004     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.055426     Document Type: Article

References (37)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
2. Jessup JM, McGinnis LS, Winchester DP, et al. Clinical highlights from the National Cancer Data Base: 1996. CA Cancer J Clin 1996;46:185-92.
3. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993;29:2077-9.
4. Labianca R, Pessi A, Facendola G, et al. Modulated 5-fluorouracil (5-FU) regimen in advanced colorectal cancer: a critical review of comparative studies. Eur J Cancer 1996;32A(Suppl 5):S7-12.
5. Levi F, Zidani R, Missel JL, et al. Randomised multicentrr trial of chemotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997;350:681-6.
6. Chen BJ. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 2001;42:253-65.
7. Chan MA, Kohlmeier JE, Branden M, et al. Triptolide is more effective in preventing T cell proliferation and interferon-gamma production than is FK506. Phytother Res 1999;13:464-7.
8. Yang Y, Liu Z, Tolosa E, et al. Triptolide induces apoptotic death of T lymphocyte. Immunopharmacology 1998;40:139- 49.
9. Huynh PN, Hikim AP, Wang C, et al. Long-term effects of triptolide on spermatogenesis, epididymal sperm function, and fertility in male rats. J Androl 2000;21:689-99.
10. Yang S, Chen J. Triptolide inhibits the growth and metastasis of solid tumors. Molecular Cancer Therapeutics 2003;2:65-72.
11. Shamon LA, Pezzuto JM, Graves JM, et al. Evaluation of the mutagenic, cytotoxic, and antitumor potential of TPL, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer Lett 1997;112:113-7.
12. Tengchaisri T, Chawengkirttikul R, Rachaphaew N, et al. Antitumor activity of TPL against cholangiocarcinoma growth in vitro and in hamsters. Cancer Lett 1998;133:169-75.
13. Jiang XH, Wong BC, Lin MC, et al. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene 2001;20:8009-18.
14. Fidler JM, Li K, Chung C, et al. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther 2003;2:855-62.
15. Lu LH, Lian YY, He GY, et al. Clinical study of triptolide in treatment of acute leukemia. Clin Exp Investig Hematol 1992;3:1-3.
16. Chou TC, Talalay P. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
17. Chou TC, Motzer RJ, Tong Y, et al. Computerized quantitation of synergism and antagonism of Taxol, topotecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-24.
18. Awad ME, Abdel-Rahman MS, Hassan SA. Acrylamide toxicity in isolated rat hepatocytes. Toxicol in Vitro 1998;12:699-704.
19. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
20. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics 2001. CA Cancer J Clin 2001;51:15-36.
21. Nordic Gastrointestinal Tumor Adjuvant Project. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992;10:904-11.
22. Scheithauer W, Rosen H, Kornek GV, et al. Randomized comparison of combination chemotherapy plus supportive care or supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752-5.
23. Kupchan SM, Court WA, Dailey RG, et al. Triptolide and tripdiolide, novel antileukemic ditepenoid tripoxides from Triterygium wilfordii. J Am Chem Soc 1972;94:7194-5.
24. Tao X, Cai JJ, Lipsky PE. The identity of immunosuppressive components of the ethyl acetate extracts and chloroform methanol extract of Tripterygium wilfordii Hook F. J Pharmacol Exp Ther 1995;272:1305- 12.
25. Yinjun L, Jie J, Yungui W. Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Leuk Res 2005;29:99-105.
26. Lou YJ, Jin J. Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leuk Lymphoma 2004;45:373-6.
27. Chang WT, Kang JJ, Lee KY, et al. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 2001;276:2221-7.
28. Zhou YX, Huang YL, Xu QN, et al. Several monomes from Tripterygium wilfordii inhibit proliferation of glioma cells in vitro. Ai Zheng 2002;21:1106-8.
29. Chan EW, Cheng SC, Sin FW, et al. Triptolide induced cytotoxic effects on human promyelocytic leukemia, T cell lymphoma and human hepatocellular carcinoma cell lines. Toxicol Lett 2001;122:81-7.
30. Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis 2002;7:313-9.
31. Green DR. Apoptotic pathways: ten minutes to dead. Cell 2005;121:671-4.
32. Wang X, Malta R, Shen G, et al. Mechanism of triptolide-induced apoptosis: effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide. J Mol Med 2006;84:405-15.
33. Yeh KH, Yeh SH, Hsu SH, et al. Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil. Br J Cancer 2000;83:1510-5.
34. Wu XX, Kakehi Y, Mizutani Y. Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol 2001;19:19-24.
35. Ikebukuro K, Adachi Y, Toki J, et al. Morphological change, loss of deltapsim and activation of caspases upon apoptosis of colorectal adenocarcinoma induced by 5-FU. Cancer Lett 2000;153:101-8.
36. Adachi Y, Taketani S, Oyaizu H, et al. Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFN-gamma through caspase-3 and caspase-8. Int J Oncol 1999;15:1191-6.
37. Matsuhashi N, Saio M, Matsuo A, et al. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs. Oncol Rep 2005;14:609-15.